uniQure N.V.

NASDAQ:QURE   3:59:46 PM EDT
41.25
+1.75 (+4.43%)
Products, Regulatory

Uniqure Announces Recommendations From Data Safety Monitoring Board Of Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington’s Disease

Published: 09/25/2020 11:35 GMT
Uniqure NV (QURE) - Uniqure Announces Recommendations From Data Safety Monitoring Board of Phase I/ii Clinical Trial of Amt-130 for the Treatment of Huntington’s Disease.
Uniqure NV - No Significant Safety Concerns Were Noted to Prevent Further Dosing, and Next Two Patients Are Now Cleared for Enrollment in Study.
Uniqure NV - Will Now Advance Amt-130 Study and Expect to Enroll Next Two Patients As Soon As Possible.